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Objective: The application of split-thickness skin grafts (STSGs) to chronic extremity wounds has often been considered
undesirable because of the perceived high incidence of failure, especially in neuropathic patients with plantar diabetic foot
wounds. The purpose of this study was to evaluate the outcomes of STSG placement in patients with chronic lower
extremity wounds.
Methods: We abstracted data from consecutive patients at our institution from January 2007 through April 2013 who
underwent STSG placement by vascular and podiatric surgeons for chronic wounds of the lower limb and foot. Patients
were monitored for at least 24 weeks, unless the wounds healed sooner.
Results: There were 94 patients (72% male) in the study group, with a mean age of 61.06 12.8 years. Of these, 66 patients
had diabetes, including 13 who were dialysis-dependent; the remaining 28 had other chronic nondiabetic wounds. The
average duration of follow-up was 12.0 6 12.9 months. After STSG placement, 65 (69.1%) experienced complete graft
incorporation and healing, and 18 (19.1%) required revision, ﬁve (5.3%) of whom ultimately required major limb
amputation. There were no differences in healing when wounds in patients with and without diabetes or plantar vs
nonplantar wound locations were compared (P > .05). Similar results were observed after adjusting the results for initial
wound size. Although dialysis patients had a threefold higher rate of STSG revision (46.2% vs 14.8%; P [ .01), the
cumulative rate of wound healing as a function of time was independent of end-stage renal disease (P [ .83).
Conclusions: The results of this study suggest that STSG may be an effective method for promotion of wound healing in
the management of chronic lower extremity wounds irrespective of wound location and presence of diabetes. (J Vasc Surg
2014;59:1657-63.)Worldwide, 371 million people are currently living
with diabetes, a number that continues to rise. In 2012
alone, $481 billion were spent to take care of these pa-
tients.1 Considering the massive effect of this disease, we
must be fully equipped to take care of all of the associated
comorbidities. As a result of associated neuropathy and pe-
ripheral vascular disease, this patient population has a sig-
niﬁcant risk of lower extremity ulceration, especially on
the weight-bearing surface of the foot. Annually, ulceration
occurs in 2% to 3% of such patients2 and at least once in
25% of people with diabetes during their lifetime, with
half becoming infected. Once infected, one in ﬁve ulcers
leads to amputation.2-4 The treatment of diabetic ulcers
is costly. The average estimated cost of treating an ulcer
in the United States in 1999 was $28,000.2
Many techniques exist to heal chronic wounds, most of
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://dx.doi.org/10.1016/j.jvs.2013.12.046graft (STSG) placement has rarely been discussed as a pri-
mary means of healing wounds, particularly those on the
diabetic foot. A recent study by Ramanujam et al5
compared STSG placement in people with and without dia-
betes, thus supporting previous work at their single center,
but they did not speciﬁcally discuss wound chronicity or
location. We are unaware of any reports in the literature
that have evaluated outcomesdand compared plantar
wounds with other anatomic locationsdin a series of pri-
marily diabetic chronic wound patients undergoing STSG
placement.
METHODS
We retrospectively analyzed the inpatient and outpa-
tient records of all consecutive patients at our institution
from January 2007 through April 2013 who underwent
STSG placement performed by vascular and podiatric sur-
geons as part of an integrated surgical limb salvage service.
All affected patients had chronic lower extremity wounds.
Patients who had undergone a fasciotomy or whose
wounds were associated with antecedent trauma were
excluded from the study.
A total of 94 patients met inclusion criteria. We exam-
ined multiple factors in the study group, including patient
age, sex, presence of diabetes, presence of dialysis-
dependent renal failure, indication for STSG, wound loca-
tion (plantar vs nonplantar), graft size, time to healing, and
ambulatory status. If ambulatory status was not stated in
the records, we presumed the patient remained ambula-
tory. Because preoperative hemoglobin A1c levels were1657
Fig 1. Example of plantar skin graft healing: wound is shown (A) before graft placement, (B) immediately after graft
placement, at (C) 3 weeks after graft placement, and (D) at 8 weeks, the wound has healed.
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lated. Wound healing was deﬁned as the presence of com-
plete graft healing and incorporation without drainage.
STSG placement was performed in a consistent fashion.
Patients required a healthy, granulation bed, which was usu-
ally aided by preoperative debridement and treatment with
a wound vacuum-assisted closure device. In the operating
room, wounds were sharply debrided to healthy, bleeding
tissue, with a surgical blade or using hydrodebridement
(Versajet; Smith & Nephew, London, UK).
Once the wound bed was adequately prepared, we har-
vested the graft (usually from the ipsilateral thigh). The
area to be harvested was anesthetized with 1% lidocaine
with epinephrine and then lubricated with mineral oil. An
electric dermatome was used to harvest the skin at a range
of 0.012 to 0.018 inches thick. The graft was then pie-
crusted or meshed at a ratio of 1.5:1 and placed onto the
wound bed. The graft was sutured in place using 4-0 chro-
mic gut sutures. Recipient sites were dressed with negative-
pressure wound therapy (NPWT) for 3 days, followed by a
compressive dressing and aggressive protection from
external pressure. The donor site was dressed with occlu-
sive petrolatum gauze with 3% bismuth tribromophenate,
4  4 gauze pad , and transparent ﬁlm dressing (Tegaderm,
St. Paul, Minn). Wounds were assessed weekly.
As part of the clinical protocol, all patients received
location-speciﬁc ofﬂoading. For plantar wounds, this
included 4 weeks of a removable cast walker (DH pressure
relief walker; Ossur, Reykjavik, Iceland), followed by total
contact casting, or instant total contact casting, as toler-
ated. Nonplantar wounds received edema-control and
trauma-protection dressings. Fig 1 depicts a typical patient
at various steps in the STSG placement process.
Data for continuous variables are reported as the
mean 6 standard deviation, and for non-normally distrib-
uted continuous variables, median values are reported.
The Kolmogorov-Smirnov test was used for testing normaldistribution of continuous variables. Between-group com-
parison was performed at 8 weeks and at the end of study
(24 weeks or until healing). We used a c2 test to assess all
dichotomous variables.
Data were grouped by presence of diabetes and plantar
or nonplantar wound location. The univariate analysis of
covariance or independent Mann-Whitney test, as appro-
priate, was used to compare the wound-healing times be-
tween groups. Patient age and sex were considered as
covariates. In addition, results were weighted according
to the initial wound size. Between-group differences for
other variables, including gender, wound size, follow-up
duration, number of healed ulcers, and number of required
revisions, were examined using analysis of variance and the
Fisher exact test or c2, as appropriate. Baseline wound size
was also dichotomized to large wound size (cutoff of
80 cm2),6 and the Kaplan-Meier test was used to compare
between-group differences for time to wound healing. The
log-rank test was used to estimate differences in wound
survival probability between groups, and the Cox regres-
sion model (forward conditional) was used to estimate sur-
vival difference between groups for time to healing, with
patient age and wound size at baseline as covariates.
Finally, to identify independent predictors for failure of
wound healing at the conclusion of the study, we used a lo-
gistic backward model. We considered failure as the depen-
dent variable and used age, gender, presence of diabetes,
location of wound (plantar or nonplantar), presence of
end-stage renal disease (ESRD), and the presence of large
wound size (wound size of $80.0 cm2) as independent
variables. A P value of# .05 was considered statistically sig-
niﬁcant. Statistical analyses were performed using SPSS 21
software (IBM Corp, Armonk, NY).
RESULTS
The study group comprised 94 patients (72.4% male)
who were a mean age of 61.0 6 12.8 years (median,
Table I. Patient and wound characteristics for patients
with and without diabetes
Variablea
Patients
without
diabetes
(n ¼ 28)
Patients
with
diabetes
(n ¼ 66) P
Age, years 63.7 6 13.5 59.8 6 12.4 .18
Gender
Male 20 (71.4) 45 (68.1) .81
Female 8 (28.6) 21 (31.8)
Location .03
Plantar 14 (50.0) 49 (74.2)
Nonplantar 14 (50.0) 17 (25.7)
Wound size, cm2 116.3 6 216.2 66.3 6 87.5 .13
Large wound size, >80 cm2 8 (28.6) 13 (19.7) .42
Follow-up duration, months 12.1 6 12.6 12.0 6 13.2 .96
Wound healing outcome
Fully healed 21 (75.0) 44 (66.7) .47
Required revision 3 (10.7) 15 (22.7) .25
Still unhealed 6 (21.4) 18 (27.2) .62
Required amputation 1 (3.6) 4 (6.0) 1
Time to successful wound
healing, weeks
8.8 6 6.5 7.2 6 4.7 .31
aContinuous data are shown as the mean 6 standard deviation and
dichotomous data as number (%).
Table II. Patient and wound characteristics for plantar
and nonplantar wounds
Variablesa
Patients
without
plantar
wounds
(n ¼ 31)
Patients
with
plantar
wounds
(n ¼ 63) P
Age, years 63.8 6 11.75 59.6 6 13.1 .13
Gender
Male 19 (61.2) 46 (73.0) .34
Female 12 (38.7) 17 (26.9)
Presence of diabetes .03
Diabetes 17 (54.8) 49 (77.8)
No diabetes 14 (45.1) 14 (22.2)
Wound size, cm2 132.7 6 216.0 50.5 6 35.8 .009
Large wound size, > 80 cm2 11 (35.4) 10 (15.8) .03
Follow-up duration, months 8.5 6 9.8 13.8 6 14.0 .06
Wound healing outcome
Fully healed 23 (74.1) 42 (66.7) .49
Required revision 5 (16.1) 13 (20.6) .25
Still unhealed 6 (19.3) 18 (28.6) .45
Required amputation 2 (6.5) 3 (4.8) 1
Time to successful wound
healing, weeks
8.1 6 5.8 7.5 6 5.1 .69
aContinuous data are shown as the mean 6 standard deviation and
dichotomous data as number (%).
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13 who were dialysis-dependent, and the remaining 28
had venous leg ulcers or other chronic nondiabetic
wounds. The average duration of follow-up was 12.0 6
12.9 months (median, 6.5 months; range, 0.5-52 months).
The mean baseline wound size was 81.66 140.3 cm2 (me-
dian, 41 cm2). The average duration of wound healing in
the successful patients was 7.7 6 5.4 weeks (median,
5.0 weeks). Patients and wound characteristics are summa-
rized in Table I.
After STSG placement, 65 patients (69.1%) experi-
enced complete wound healing. The 29 patients whose
wounds did not heal were treated with a combination of
local wound care and healing by secondary intention. At
the end of the study, the wounds in 70 patients (74.5%)
were successfully healed, and 19 (20.2%) failed to heal.
Five patients (5.3%) required amputation. To further
examine the effect of diabetes and wound location on out-
comes of wound healing, participants were classiﬁed as dia-
betes vs no-diabetes (Table I) and as plantar wound vs
nonplantar wound (Table II).
Patients with and without diabetes had a similar gender
distribution (71.4% vs 68.1% male). The mean age was
63.7 6 13.5 years in the overall study population and
was similar, at 59.8 6 12.4 years, for those in the diabetes
subgroup (P ¼ .18). Patient age and gender did not appear
to signiﬁcantly affect outcome (P > .05). No differences
between groups were observed for the initial wound size,
number of patients with large wound size (wound size of
$80 cm2), and the duration of follow-up (Table I). How-
ever, the proportion of plantar wounds was higher in the
diabetic group (74.2%) compared with those without dia-
betes (50.0%; P ¼ .03). When wounds were comparedby presence of diabetes, no differences were observed for
the number of fully healed patients, the requirement for
revision, or ambulatory status. Of the 66 patients with dia-
betes, wounds in 44 (66.7%) healed primarily after STSG
placement, without revision or without the requirement
for secondary healing, compared with 21 (75.0%) of the
nondiabetic patients. Similarly, wounds in 18 (27.2%)
failed to heal in the diabetic group vs six (21.4%) in nondi-
abetic group (Table I). A similar proportion of diabetic
wounds (50.0%) healed in 8 weeks compared with nondi-
abetic wounds (48.0%; P ¼ .44).
The mean time to wound healing was 7.2 6 4.7 weeks
in patients with diabetes compared with 8.86 6.5 weeks in
those without diabetes. The difference of 1.6 weeks was
not signiﬁcant (95% conﬁdence interval,4.7 to 1.5 weeks;
P ¼ .31). Wounds that were >80 cm2 at baseline were less
likely to heal, with a 52% success rate in the group with a
large wound vs 74% success rate in the group with a
small-sized wound (c2 ¼ 3.56, P ¼ .05). The mean wound
size in patients without diabetes was 116.3 6 216.2 cm2,
which was greater than the mean area of 66.3 6
87.5 cm2 in those with diabetes; however, the difference
was not signiﬁcant (P ¼ .13). We observed no signiﬁcant
difference in wound-healing time between those with and
without diabetes after we weighted the results by (and
thus controlled for) initial wound size (P ¼ .7). Fig 2 illus-
trates the patient survival curve by time to wound healing
as a function of the presence or absence of diabetes. Results
suggest no signiﬁcant difference in time to healing by pres-
ence of diabetes with the numbers available for assessment
(c2 ¼ 0.315, P ¼ .57). Age and baseline wound size were
also not signiﬁcant predictors in our time-to-event model.
Fig 2. Wound-healing time is shown for diabetic wounds vs
nondiabetic wounds.
Fig 3. Wound healing time is shown for plantar vs nonplantar
wounds.
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tion, we did not detect a signiﬁcant difference in wound
healing between plantar and nonplantar wounds (7.5 6
5.1 vs 8.1 6 5.8 weeks; P ¼ .69), 0.6 weeks (95% con-
ﬁdence interval, 3.63 to 2.4 weeks). Most plantar
wounds were in the diabetic group (77.8%) compared
with 22.2% in the nondiabetic group (P ¼ .03). Wound
size and number of patients with large wound size
($80 cm2) were higher in the nonplantar wound group
compared with planar wound group (P < .05). Despite
these observed differences, the outcomes of wound heal-
ing, including number of successfully healed, number
requiring revision, and number of amputations, were the
same between groups (P > .05; Table II). Fig 3 illustrates
the patient survival curve by time to wound healing as a
function of anatomic location. There was no signiﬁcant
difference in time to healing by wound location (c2 ¼
0.522; P ¼ .47). According to the Cox regression model,
baseline wound size and patient age were not signiﬁcant
predictors of time to healing when we compared patients
with and without diabetes. A similar proportion of plantar
wounds healed in 8 weeks (57.1%) compared with non-
plantar wounds (67.4%; P ¼ .44).
We also evaluated the effect of ESRD on wound heal-
ing (Table III). Overall, the outcomes of wound healing
were the same between patients with and without ESRD.
However, ESRD patients had a threefold higher rate of
revision of 46.2% vs 14.8% without (P ¼ .01). Time-to-
event analysis suggests that the cumulative survival forsuccessful wound healing as a function of time is indepen-
dent of ESRD status (c2 ¼ 0.045; P ¼ .83).
Considering many of our patients have concomitant
vascular disease, we also evaluated whether revasculariza-
tion before STSG affected wound healing compared with
patients who did not require revascularization based on
physical examination and the results of noninvasive testing
(Table IV). Thirty-seven patients had a revascularization
procedure before undergoing STSG. Of those, 19
(51.4%) were performed by an endovascular approach, 16
(43.2%) were open surgical bypasses, and two (5.4%) had
open and endovascular procedures. Overall, there was no
difference in outcomes in patients who did and did not
require revascularization before STSG. However, patients
with diabetes were more likely to have been revascularized
before STSG (P ¼ .005). Increasing age also increased the
likelihood of being revascularized (P ¼ .002).
Finally, the logistic regression model identiﬁed only the
presence of a large wound as an independent predictor for
failure to heal (P ¼ .04).
DISCUSSION
STSG placement has not traditionally been recommen-
ded for treating diabetic foot wounds, particularly those on
the plantar, weight-bearing surface. There is a paucity of
literature describing the ideal management of such
wounds. Even less has been published supporting STSG
placement, even though skin grafting has been performed
for centuries. In 2500 to 3000 B.C., members of a Hindu
Table III. Effect of end-stage renal disease (ESRD) on
wound healing
Variablea
Patients
without
ESRD
(n ¼ 81)
Patients
with
ESRD
(n ¼ 13) P
Age, years 60.5 6 13.3 64.2 6 8.2 .34
Gender
Male 57 (70.0) 8 (61.5) .53
Female 24 (29.6) 5 (38.5)
Location .75
Plantar 55 (67.9) 5 (38.5)
Nonplantar 26 (32.1) 8 (61.5)
Wound size, cm2 86.5 6 149.7 49.4 6 34.3 .66
Large wound size, >80 cm2 19 (23.4) 2 (15.4) .42
Follow-up duration, months 15.3 6 7.0 16.5 6 10.2 .71
Wound healing outcome
Fully healed 56 (69.1) 9 (69.2) 1
Required revision 12 (14.8) 6 (46.2) .01
Still unhealed 20 (24.6) 4 (30.7) .35
Required amputation 5 (6.1) 0 (0) 1
Time to successful wound
healing, weeks
7.6 6 5.3 8.3 6 6.2 .77
aContinuous data are shown as the mean 6 standard deviation and
dichotomous data as number (%).
Table IV. Beneﬁt of revascularization on wound healing
Variablea
Patients without
revascularization
(n ¼ 57)
Patients with
revascularization
(n ¼ 37) P
Age, years 57.7 6 14.3 66.1 6 7.6 .002b
Gender
Male 14 (24.6) 15 (40.5) .11
Female 43 (75.4) 22 (59.5)
Location .93
Plantar 38 (66.7) 25 (67.6)
Nonplantar 19 (33.3) 12 (32.4)
Presence of diabetes 34 (59.6) 32 (86.4) .005b
Presence of ESRD 6 (10.5) 7 (18.9) .25
Wound size, cm2 81.3 6 150.4 81.9 6 126.0 .28
Large wound size,
>80 cm2
12 (21.0) 9 (24.3) .8
Follow-up duration,
months
15.4 6 10.3 15.7 6 9.4 .88
Wound healing
outcome
Fully healed 39 (68.4) 26 (70.3) .85
Required revision 10 (17.5) 8 (21.6) .78
Still unhealed 15 (26.3) 9 (24.3) .83
Required
amputation
3 (5.3) 2 (5.4) .97
Time to successful
wound healing,
weeks
7.1 6 5.7 8.7 6 4.8 .28
ESRD, End-stage renal disease.
aContinuous data are shown as the mean 6 standard deviation and
dichotomous data as number (%).
bStatistically signiﬁcant (P < .05).
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nose, and as early as 1872, Ollier and Thiersch described
the technique of STSG placement.7 However, given our
own experience, supported by one other report in the liter-
ature,5 we recommend performing STSG placement to
heal chronic diabetic foot wounds. This is true even in
select cases on the plantar surface.
In addition, as described in this study, we routinely use
NPWT as an adjunct to prepare the wound bed before
grafting and to postoperatively bolster the STSG. Advan-
tages of using NPWT as a bolster dressing include
improved graft take, ready conformance in difﬁcult
anatomic areas, ease of application, reduction in seroma
and hematoma formation, and improved ability of patients
to ambulate despite the dressing.8 Moisidis et al,9 in a ran-
domized controlled trial, showed improved epithelializa-
tion and better STSG quality in patients who were
treated with NPWT, a beneﬁt the authors attributed to
increased oxygenation at the site and continuous removal
of exudate and bacteria.
Several groups have reported success in healing diabetic
wounds with STSG placement. In a review of 83 diabetic
patients who underwent STSG placement for foot wounds,
Ramanujam et al10 found that 65% experienced initial graft
take within 7 weeks postoperatively. The grafts that failed
tended to require reoperation. Graft failures were more
common in smokers and in patients with a wound infection.
In a study of people with diabetes undergoing STSG
placement for wound healing compared with conservative
care with a standard parafﬁn gauze and iodine dressing,
Mahmoud et al11 found that 86% of the STSG patients
healed at 8 weeks in contrast to only 46% in the
conservative-care group. They also reported that morerapid healing time translated into decreased hospital length
of stay and overall decreased cost of care.11
In a review of 107 patients undergoing STSG place-
ment after debridement and control of diabetic foot infec-
tions, Anderson et al12 found that the mean time to healing
was 5.1 weeks, with a complication rate of only 2.8%. Put-
tirutvong13 reported that meshed STSG placement yielded
consistent healing in people with diabetes.
Of note, although the literature in this area is sparse,
McCartan and Dinh14 performed a meta-analysis of the
few available publications on STSG placement for diabetic
wounds. They computed a graft take rate of $90% in 78%
of patients by 8 weeks, and therefore recommended it as a
viable option in wound care.
In a retrospective review ofw200 patients undergoing
STSG placement for foot wounds, Ramanujam et al5 found
that comorbidities associated with diabetes, such as periph-
eral vascular disease, retinopathy, nephropathy, and cardio-
vascular disease, conferred more risk of graft failure than
the diabetes itself. In the present study, we did not thor-
oughly evaluate patient comorbidities; however, it is
possible that the graft failures we observed were in patients
with a higher comorbidity index. Therefore, we now
believe that, when choosing a closure method for diabetic
foot wounds, it may be prudent to consider other impor-
tant comorbidities and not just the presence or absence
of diabetes or ESRD. This was at least partially conﬁrmed
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requiring revision surgery.
There are several other factors that would, at ﬁrst
blush, seem to play a signiﬁcant role in risk for nonhealing.
Two of these might include plantar location of the wound
and preprocedure revascularization. Because this study was
not speciﬁcally powered to identify these ﬁndings, it is
entirely plausible that a prospective inquiry might show
objective differences. We look forward to further works
that can conﬁrm or refute these speculations.
In the present study, we found that STSG placement
enabled problematic wounds to heal successfully in many
patients, although a minority did not, and a few went on
to undergo an amputation. We did not look speciﬁcally
into why, but many factors could contribute to these fail-
ures; the most likely causes were comorbidities, wound
size, and infection. Wound size clearly played a substantial
role, because wounds >80 cm2 were less likely to heal with
complete graft take. An observational study by Oyibo
et al15 reported that the greater the cross-sectional area
of the wound, the more likely it was for patients to experi-
ence difﬁculty healing or to require amputation. Oyibo
et al15 concluded that ischemia, wound depth, and infec-
tion also negatively affected wound healing, a conclusion
we previously also published.16
The new Society for Vascular Surgery threatened limb
classiﬁcation system, Wound, Ischemia, and foot Infection
(WIfI), was partly designed to allow analysis of these fac-
tors critical to healing, because not only ischemia but also
wounds and infection are included in WIfI and are graded
for severity.16
Although STSG placement is a viable option to achieve
wound healing, the technique does have drawbacks
compared with the use of full-thickness grafts and ﬂaps.
Full-thickness grafts and ﬂaps, for example, are more likely
than STSGs to enable patients to have sensation postoper-
atively. STSGs also diminish the patient’s ability to differen-
tiate temperature (ie, to detect whether an object is cold or
hot).17 However, given that most patients in need of grafts
are already neuropathic, lack of sensation after STSG place-
ment is not likely to be an issue of primary concern.
Other advantages of full-thickness grafts and ﬂaps are
their tendency to be more mobile and their lower suscepti-
bility to hyperkeratosis and ﬁssuring than STSGs, according
to Sommerlad and McGrouther.17 However, their study
described repair of the plantar foot most commonly to treat
traumatic lesions; the presence of diabetes was not re-
ported. In the present study of a primarily diabetic popula-
tion with difﬁcult-to-heal chronic wounds, we found ﬂorid
hyperkeratosis surrounding STSGs to be uncommon. In
sensate, nondiabetic traumatic wounds, full-thickness grafts
and ﬂaps may well be preferable; in contrast, in diabetic pa-
tients with chronic wounds, rapid primary healing might be
a major therapeutic goal and, thus, STSGs might be more
suitable.
For patients concerned about undergoing an opera-
tion, tissue-engineered skin grafts are another option; how-
ever, the take rate of such grafts is lower than that ofautologous STSGs. One can also argue that they do not
act as a graft at all, but rather as a delivery system for cyto-
kines and chemokines. Still, tissue-engineered grafts do not
require harvest and, therefore, obviate the need for and
risks of anesthesia and postoperative hospitalization. The
only true loss if tissue-engineered grafts fail is the cost of
the graft itself and the time expended using them.18
CONCLUSIONS
The results of this study suggest that STSG is an effec-
tive method for management of wound healing irrespective
of wound location and the presence of diabetes. The data
support the use of such grafts as a viable option in the
care of dorsal and plantar diabetic foot wounds. We also
believe that the use of postoperative NPWT may simplify
graft dressing and facilitate incorporation and healing.
We thank Mary Knatterud, PhD, for her assistance with
manuscript review.
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tremity wounds are different with respect to their etiologies and
can at times be treated with seemingly contradictory management
strategies. In this study, the authors examined 94 chronic wounds
after skin grafting. The common denominators were skin grafts.
Overall, 69% of patients healed their wounds with skin grafts.
The authors did not explain why the other 31% did not heal. Com-
parisons between type and location of the ulcer showed no differ-
ence. I have the following questions:
1. What is the deﬁnition of “high-risk diabetic feet?”
2. Why were nondiabetic wounds used as the comparison group?
Nondiabetic wounds, such as venous ulcers, have a different
etiology, pathophysiology and prognosis compared with dia-
betic ulcers. So, isn’t this a comparison of apples vs oranges?
3. What type of diabetic wounds were examined; were they
neuropathic, mixed, or of ischemic etiologies? Presumably,
the mixed and ischemic diabetic ulcers had their underlying
ischemia corrected.
4. For plantar wounds, were they on a weight-bearing surface or
not?
5. What were the healing rates for split-thickness skin grafts
(STSGs) placed on weight-bearing compared with non-
weight-bearing surfaces in diabetic patients?
6. What were the recurrence rates of these ulcers?
Dr Jessica F. Rose. Thank you very much for the questions.
1. We deﬁned patients as “high risk” in this population that had
diabetes with active wounds requiring surgical intervention.
Indeed, risk for limb loss is a spectrumdranging from the
non-neuropathic low-risk patient with diabetes to a patient
with severe peripheral arterial disease and ESRD. It is in part
to better deﬁne this term that compelled members of our
research team and other members of the Society for Vascular
Surgery to create an updated threatened limb classiﬁcation sys-
tem for the at-risk limb based on the factors of Wound,
Ischemia, and degree of Foot Infection, colloquially known
as WIfI.2. We abstracted records from our patient population undergo-
ing STSGs to heal chronic wounds. We realize that these
wounds have a very different etiology. Historically, STSGs
were considered to be relatively contraindicated as a method
to heal diabetic, plantar wounds. We sought to see if this pop-
ulation had more difﬁculty healing than those with other
chronic wounds in a sample treated consistently by surgeons
in a closely-knit clinical and research team. These patients
were the logical comparison groups based on our study design.
Future prospective work might allow us to draw conclusions
without mixing various types of clinical fruits and vegetables.
3. We examined all different types of diabetic wounds. Those
that were ischemic had the malperfusion corrected before
STSG placement. We did analyze whether preoperative
correction had any effect on our study population.
4. Based on our registry, we could only determine if the wounds
were on the plantar surface or not, but we lacked sufﬁciently
speciﬁc information to determine if the index wound was
truly over the weight-bearing area. Therefore, those on the
plantar surface were presumed to be weight-bearing. Howev-
er, the essence of our interdisciplinary team consisting of
vascular and podiatric surgeons, as well as orthotists and pros-
thetists, is to focus on spreading a potentially deleterious
force out over a larger unit area. This approach mitigates
pressure and, we believe, mitigates risk by increasing likeli-
hood for healing.
5. We found that 66.7% of those with plantar wounds and 74.1%
of nonplantar wounds were healed. These values were not clin-
ically or statistically signiﬁcantly different (P ¼ .5)
6. We did not have any recurrences during the duration of the
study. That is the subject for future works that our unit is
currently undertaking. We believe strongly that durability of
correction depends on a number of factors. One such factor
may be the viscoelastic characteristics of skin, but just as
much may be the characteristics of shoe gear modiﬁcation
and activity prescription.
